This item is the archived peer-reviewed author-version of:

How strict is galactose restriction in adults with galactosaemia? International practice

Reference:

Adam S., Akroyd R., Bernabei S., De Meyer Anke, Luyten K., et al.- How strict is galactose restriction in adults with galactosaemia? International practice

Molecular genetics and metabolism - ISSN 1096-7192 - 115:1(2015), p. 23-26

Full text (Publishers DOI): <http://dx.doi.org/doi:10.1016/j.ymgme.2015.03.008>

To cite this reference: <http://hdl.handle.net/10067/1263780151162165141>

Accepted Manuscript

How strict is galactose restriction in adults with galactosemia? International practice

S. Adam, R. Akroyd, S. Bernabei, S. Bollhalder, S. Boocock, A. Burlina, T. Coote, K. Corthouts, J. Dalmau, S. Dawson, S. Defourny, A. De Meyer, A. Desloovere, Y. Devlin, M. Diels, K. Dokoupil, S. Donald, S. Evans, I. Fasan, C. Ferguson, S. Ford, M. Forga, G. Gallo, S.C. Grünert, M. Heddrich-Ellerbrok, C. Heidenborg, C. Jonkers, K. Lefebure, K. Luyten, A. MacDonald, U. Meyer, A. Micciche, E. Müller, P. Portnoi, S. Ripley, M. Robert, L.V. Robertson, S. Rosenbaum-Fabian, K. Sahm, S. Schultz, K. Singleton, E. Sjöqvist, L. Stoelen, A. Terry, S. Thompson, C. Timmer, K. Vande Kerckhove, L. van der Ploeg, M. Van Driessche, M. van Rijn, A. van Teeffelen-Heithoff, I. Vitoria, C. Voillot, J. Wenz, M. Westbrook, J. Wildgoose, H. Zweers

PII: S1096-7192(15)00088-8
DOI: doi: [10.1016/j.ymgme.2015.03.008](https://doi.org/10.1016/j.ymgme.2015.03.008)
Reference: YMGME 5897

To appear in: *Molecular Genetics and Metabolism*

Received date: 12 February 2015
Revised date: 29 March 2015
Accepted date: 30 March 2015

Please cite this article as: Adam, S., Akroyd, R., Bernabei, S., Bollhalder, S., Boocock, S., Burlina, A., Coote, T., Corthouts, K., Dalmau, J., Dawson, S., Defourny, S., De Meyer, A., Desloovere, A., Devlin, Y., Diels, M., Dokoupil, K., Donald, S., Evans, S., Fasan, I., Ferguson, C., Ford, S., Forga, M., Gallo, G., Grünert, S.C., Heddrich-Ellerbrok, M., Heidenborg, C., Jonkers, C., Lefebure, K., Luyten, K., MacDonald, A., Meyer, U., Micciche, A., Müller, E., Portnoi, P., Ripley, S., Robert, M., Robertson, L.V., Rosenbaum-Fabian, S., Sahm, K., Schultz, S., Singleton, K., Sjöqvist, E., Stoelen, L., Terry, A., Thompson, S., Timmer, C., Vande Kerckhove, K., van der Ploeg, L., Van Driessche, M., van Rijn, M., van Teeffelen-Heithoff, A., Vitoria, I., Voillot, C., Wenz, J., Westbrook, M., Wildgoose, J. & Zweers, H., How strict is galactose restriction in adults with galactosemia? International practice, *Molecular Genetics and Metabolism* (2015), doi: [10.1016/j.ymgme.2015.03.008](https://doi.org/10.1016/j.ymgme.2015.03.008)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

HOW STRICT IS GALACTOSE RESTRICTION IN ADULTS WITH GALACTOSEMIA? INTERNATIONAL PRACTICE

Adam S¹; Akroyd R²; Bernabei S³; Bollhalder S⁴; Boocock S⁵; Burlina A⁶; Coote T²; Corthouts K⁷; Dalmau J⁸; Dawson S⁹; Defourny S¹⁰; De Meyer A¹¹; Desloovere A¹²; Devlin Y¹³; Diels M⁷; Dokoupil K¹⁴; Donald S¹⁵; Evans S¹⁶; Fasan I⁶; Ferguson C¹³; Ford S¹⁷; Forga M¹⁸; Gallo G³; Grünert SC¹⁹; Heddrich-Elberbrok M²⁰; Heidenborg C²¹; Jonkers C²²; Lefebure K²³; Luyten K¹¹; MacDonald A¹⁶; Meyer U²⁴; Micciche A²⁵; Müller E²⁶; Portnoi P²⁷; Ripley S²⁸; Robert M¹⁰; Robertson LV⁵; Rosenbaum-Fabian S¹⁹; Sahm K²⁶; Schultz S²⁰; Singleton K²⁹; Sjöqvist E³⁰; Stoelen L³¹; Terry A³²; Thompson S³³; Timmer C³⁴; Vande Kerckhove K⁷; van der Ploeg L³⁵; Van Driessche M¹²; van Rijn M³⁶; van Teeffelen-Heithoff A³⁷; Vitoria I⁸; Voillot C³⁸; Wenz J³⁹; Westbrook M⁴⁰; Wildgoose J⁴¹; Zweers H⁴²

¹Royal Hospital for Sick Children, Glasgow, UK; ²National Metabolic Service, Starship Children's Health and Auckland City Hospital, Auckland, New Zealand; ³Ospedale pediatrico Bambino Gesù, Rome, Italy; ⁴UniversitätsSpital Zürich, Switzerland; ⁵University Hospitals Birmingham NHS Foundation Trust, UK; ⁶Division of Inherited Metabolic Diseases, Reference Centre Expanded Newborn Screening, Department of Pediatrics, University Hospital, Padova, Italy; ⁷University Hospitals Leuven, Center of metabolic diseases, Belgium; ⁸Hospital La Fe, Valencia, Spain; ⁹Royal Hospital for Sick Children Edinburgh; ¹⁰Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium; ¹¹Center of Metabolic Diseases, University Hospital, Antwerp, Belgium; ¹²Universitair Ziekenhuis Gent, Belgium; ¹³Royal Victoria Hospital, Newcastle, UK; ¹⁴Dr. von Hauner Children's Hospital, Munich, Germany; ¹⁵Addenbrookes, Cambridge, UK; ¹⁶Birmingham Children's Hospital, Birmingham, UK; ¹⁷North Bristol NHS Trust Southmead and Frenchay, UK; ¹⁸Hospital Clinic Barcelona, Spain; ¹⁹University Children's Hospital Freiburg, Germany; ²⁰Universitätsklinikum Hamburg-Eppendorf, Germany; ²¹Karolinska University Hospital Stockholm, Sweden; ²²Academic Medical Hospital, Amsterdam, Netherlands; ²³Royal Melbourne Hospital, Melbourne, Australia; ²⁴Clinic of Paediatric Kidney, Liver- and Metabolic Diseases Medical School Hannover, Germany; ²⁵St Thomas' Hospital, London, UK; ²⁶Children's Hospital Heidelberg, Germany; ²⁷Galactosemia Support Group, UK; ²⁸Salford Royal, Manchester, UK; ²⁹University Hospital of Wales, Cardiff, UK; ³⁰Children's Hospital, University Hospital Skåne, Sweden; ³¹Oslo University Hospital Rikshospitalet, Norway; ³²Alderhey Children's Hospital, Liverpool, UK; ³³Children's Hospital, Westmead, Sydney, Australia; ³⁴UMC Utrecht, Netherlands; ³⁵University Hospital Maastricht, Netherlands; ³⁶University of Groningen, University Medical Center Groningen, Netherlands; ³⁷Univ.-Kinderklinik, Pädiatrische Diätetik, Munster, Germany; ³⁸Hôpital Antoine Bécère, France; ³⁹CHU Bicêtre Hospital, Paris, France; ⁴⁰Westmead Hospital, Sydney, Australia; ⁴¹Bradford Teaching Hospital NHS Trust, UK; ⁴²Radboud UMC, Netherlands

Correspondence to:

Anita MacDonald
Dietetic Department
Birmingham Children's Hospital
Steelhouse Lane
Birmingham, B4 6NH
Tel: 01213338024
Fax: 01213338020
Email: anita.macdonald@bch.nhs.uk

ABSTRACT

Dietary management of 418 adult patients with galactosaemia (from 39 centres/12 countries) was compared. All centres advised lactose restriction, 6 restricted galactose from galactosides $\pm$ fruits and vegetables and 12 offal. 38% (n=15) relaxed diet by: 1) allowing traces of lactose in manufactured foods (n=13) or 2) giving fruits, vegetables and galactosides (n=2). Only 15% (n=6) calculated dietary galactose. 32% of patients were lost to dietetic follow-up. In adult galactosaemia, there is limited diet relaxation.

Key words: Galactosemia, galactose, lactose, galactose-1-phosphate, diet, monitoring.

1. INTRODUCTION

There has been considerable debate regarding the necessity for severe galactose restriction in older patients with galactosemia. Patient support groups are posing questions about the essentiality of life-long strict diet and some adults with galactosemia may already follow a self-relaxed diet. Although poor dietary control beyond infancy has been associated with cataract formation [1,2] and increases in biochemical markers [3], overall life-long dietary restriction does not appear to play a significant role in determining the severity of cognitive outcomes [4-6]. In practice, there is little data about the dietary management of adult patients and many are lost to dietetic follow up [7]. There are only a few adult case reports of patients homozygous for the severe mutation Q188R who have self-liberated galactose-intake without obvious adverse effects [8-10]. In order to assess the extent of diet relaxation in adult clinical practice, this international survey was conducted to examine dietary advice given to adults with galactosaemia.

2. MATERIALS AND METHODS

2.1 Study design

A questionnaire (17 multiple choice and short answer questions) relating to dietary advice to adult patients with galactosaemia, was sent to dietetic members of the Society for the Study of Inborn Errors of Metabolism (SSIEM) and Australasian Society for Inborn Errors of Metabolism (ASIEM). Dietitians were requested to cascade this questionnaire to other dietetic colleagues within their country. In this cross-sectional audit, data from each clinic was collected about the severity of dietary restriction (quantity of galactose allowed; restriction of galactosides, galactose in fruit and vegetables, offal; and cheese permitted), any dietary changes by patient or dietitian specifically in adulthood, circumstances when dietary treatment might be relaxed, regularity of follow up; and frequency of galactose-1-phosphate (Gal-1-P) monitoring. Data on patient genotype, long term patient outcome and biochemical data was not included in this audit. Ethical approval was not required as no specific identifiable patient data was obtained.

3. RESULTS

Questionnaires were returned from 39 European and Australasian international IMD centres providing data on 418 adult patients with galactosaemia from 12 countries (Table 1). Each individual centre regularly treated between 1 and 24 adult patients (median: 8 patients) with galactosaemia.

3.1 Overall dietary restrictions. (Table 1) All centres recommended lactose restriction in adult patients, but there was some galactose restriction from fruits and vegetables (4/39) and galactosides (6/39) and 12/39 centres limited offal intake. Only one centre in Spain did not permit any low lactose cheese.

3.2 Relaxed diets: In adults, diets were relaxed in 15 centres (38%) from 6 countries (Table 1), but mainly self-directed by patients than dietitians. Centres advising a lactose-free diet only, relaxed diets with trace amounts of lactose in manufactured foods such as breads, biscuits, and cakes (e.g., lactose in sodium and calcium caseinates, animal fats, flavourings) (estimated galactose: <20 mg/portion) or margarine and butter on sandwiches (estimated galactose: up to 200 mg/sandwich) purchased in retail outlets. Centres in France permitted all fruits, vegetables and galactosides and so advised a lactose-free diet only. Although information was not collected about metabolic control, no dietitians reported development of symptoms as a consequence of these small changes.

3.3 Calculation of galactose intake: Most centres (85%, n=33) did not formally calculate the amount of galactose in the diet. One centre (Belgium) allowed only 50mg /day, 2 centres (Italy, Netherlands) 100mg/day, 1 centre (Belgium) 300mg/day, 1 centre (Germany) 300-500mg/day, and 1 centre (Germany) 500mg/day.

3.5 Follow-up: Patients were monitored by dietitians annually by the majority of centres (67%, n=26). Thirty-two percent (n=132) of patients were lost to dietetic follow up (definition: no contact for at least 2 years). Reasons for lack of follow up included: patient relocation, regular follow up by physicians but not dietitians, and patient choice only to attend clinics according to need e.g. pregnancy and genetic counseling.

Gal-1-P measurements were monitored by half of the centres (n=20) annually and 14 (36%) rarely or never monitored this biochemical marker.

4. DISCUSSION

This is the first international multi-centre study to describe dietetic management practices in adult patients with galactosemia. It is clear there is uncertainty regarding the requirement for strict diet in adulthood. Although over 75% of centres considered that a strict diet was necessary, lower patient dietary adherence associated with less health professional conviction for the need for strict diet led to a very cautious approach in moderating dietary restriction. Advice in adulthood was also influenced by severity of childhood restriction (lactose free only vs low galactose). To our knowledge no adult suffered from symptoms as a consequence of small dietary changes but there was limited monitoring of biochemical control. It was disturbing that almost a third of patients were lost to dietetic follow up, and some were reviewed by a medical physician without dietetic follow-up. Treatment centres should strive to maintain long-term dietetic follow-up of all patients.

Disappointingly, there was still rigorous restriction of galactose extending beyond lactose restriction (elimination of galactose from some fruit and vegetables, galactosides and galactose storage organs) by a small number of centres. There is little evidence to support this practice, and a recent USA review recommended that fruits, vegetables, legumes and non-fermented soya products are given without restriction in a low galactose diet [11] to all age groups.

In conclusion, almost 40% of IMD centres relax diet in classical galactosemia, but any change is commonly patient led and small (<200 mg/day galactose). Additional galactose intake was not usually quantified, generally hampered by a lack of reliable data on the galactose content of foods. Although it is essential that further prospective multi-centre research examining individual galactose tolerance is conducted before recommendation on diet relaxation is given, health professionals should report the outcome of individual adult patients on less restrictive diets, and any galactose intake should be systematically estimated at clinic review.

REFERENCES:

1. Beigi B, O'Keefe M, Bowell R, Naughten E, Badawi N, Lanigan B. Ophthalmic findings in classical galactosemia – prospective study. *Brit J Ophth.* 1993;77:162-164.
2. Widger J, O'Toole J, Geoghegan O, O'Keefe M, Manning R. Diet and visually significant cataracts in galactosemia: is regular follow up necessary? *J Inherit Metab Dis.* 2010;33:129-32.
3. Berry GT, Elsas LJ. Introduction to the Maastricht workshop: lessons from the past and new directions in galactosemia. *J Inherit Metab Dis.* 2011;34:249-55.
4. Fridovich-Keil JL, Walter JH. Galactosemia. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A eds, Scriver CR, Childs B, Sly W (Emeritus eds), *The Online Metabolic and Molecular Bases of Inherited Disease*. New York: McGraw-Hill; 2008. p. 1-64.
5. Jumbo-Lucioni PP, Garber K, Kiel J, Baric I, Berry GT, Bosch A, et al. Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes. *J Inherit Metab Dis.* 2012;35:1037-49.
6. Shield JP, Wadsworth EJ, MacDonald A, Stephenson A, Tyfield L, Holton JB, et al. The relationship of genotype to cognitive outcome in galactosemia. *Arch Dis Child.* 2000;83:248-50.
7. Waisbren SE, Potter NL, Gordon CM, Green RC, Greenstein P, Gubbels CS, et al. The adult galactosemic phenotype. *J Inherit Metab Dis.* 2012;35:279-86.
8. Lee PJ, Lilburn M, Wendel U, Schadewaldt P. A woman with untreated galactosemia. *Lancet.* 2003;362:446.
9. Panis B, Bakker JA, Sels JP, L.J.Spaapen, van Loon LJ, Rubio-Gozalbo ME. Untreated classical galactosemia patient with mild phenotype. *Mol Genet Metab.* 2006;89:277-279.
10. Coman DJ, Murray DW, Byrne JC, Rudd PM, Bagaglia PM, Doran PD, et al. Galactosemia a single gene disorder with epigenetic consequences. *Pediatr Res.* 2010;67:286-92.
11. Van Calcar SC, Bernstein LE, Rohr FJ, Scaman CH, Yannicelli S, Berry GT. A re-evaluation of life-long severe galactose restriction for the nutrition management of classic galactosemia. *Mol Genet Metab.* 2014; 112: 191-7.

CONFLICTS OF INTEREST:

Sarah Adam - funding from SHS and Vitaflo to attend study days and conferences.

Rhonda Akroyd – funding from SHS and Vitaflo to attend study days and conferences.

Alberto Burlina - honoraria from Nutricia, and Merck Serono, Member of Sapropterin Advisory Board (Merck Serono international), Member of the Advisory Board Element (Danone-Nutricia).

Karen Corthouts – support from Nutricia, Vitaflo, Merck Serono to attend independent or industry-organised trainings and conferences.

Marianne Diels - support from Nutricia, Vitaflo, Merck Serono to attend independent or industry-organised trainings and conferences.

Katharina Dokoupil - Member of the European Nutrition Expert Panel (Merck Serono international)

Sharon Evans - a research dietitian funded by Nutricia; financial support from Nutricia and Vitaflo to attend study days and conferences.

Carina Heidenborg - Honoraria for lecturing and funding to attend study days and conferences.

Anita MacDonald - research funding and honoraria from Nutricia, Vitaflo International and Merck Serono, Member of European Nutrition Expert Panel (Merck Serono international), Member of Sapropterin Advisory Board (Merck Serono international), Member of the Advisory Board Element (Danone-Nutricia).

Edith Mueller – honoraria from Danone Trading B.V. for lecturing and training materials evaluation, honoraria from Vitaflo for training materials development.

Pat Portnoi – sponsorship from Nutricia and Vitaflo to attend conferences and study days.

Margreet van Rijn - Danone Research and Development consultant, Member of the Advisory Board ELEMENT (Danone-Nutricia), Financial research support of Nutricia Netherlands, Honoraria for lecturing and guideline development (Nutricia, Orphan Europe, SSIF).

Marine Robert – member of the European Nutrition Expert Panel (Merck Serono International)

Louise Robertson - funding from SHS and Vitaflo to attend study days and conferences, market research funding from Nutricia.

Linn Helene Stolen – travel/accommodation/meeting expenses from Nutricia and Vitaflo.

Susan Thompson – funding from Vitaflo of part time nutrition education assistant for the Genetic Metabolic Disorder Service, The Children's Hospital at Westmead, funding towards conference attendance by Biomarin, Cortex Health, Menarini, Nutricia and Vitaflo through ASIEM travel grants.

Corrie Timmer – travel/accommodation/meeting expenses from Nutricia and Vitaflo.

Liesbeth van der Ploeg – funding from Nutricia and Vitaflo to attend study days and conferences.

Kristel Vande Kerckhove - support from Nutricia, Vitaflo, Merck Serono to attend independent or industry-organised trainings and conferences.

Catherine Voillot – support from Nutricia; travel accommodation and meeting expenses from Vitaflo.

Joelle Wenz - honoraria from Nutricia; recipes calculate and from SOBI for Tyrosinaemia type 1 guideline and workshop on UCD widget; travel accommodation and meeting expenses from Nutricia, SHS, Vitaflo, SOBI, Lactalis.

AUTHORS' CONTRIBUTIONS:

All authors were involved in data collection, interpretation of data, critical revision of the paper for important intellectual content and final approval of the version to be published. Anita MacDonald and Pat Portnoi were additionally involved in the initial conception and design and Anita MacDonald and Sharon Evans in the collation of data and drafting of the initial article.

ACKNOWLEDGEMENTS

Source of funding: There has been no formal funding for this study and no aspect of this work in terms of funding, data monitoring, study design, manuscript preparation, statistical analysis etc. has been affiliated with any third parties.

Table 1: Dietary treatment policy and diet relaxation practices for adults with galactosaemia reported by centres

Country represented by participating centres	No. of centres from each country	Total number of patients	Dietary treatment policy – restricted foods				Allow relaxed diet	Reasons for diet relaxation				Types of foods permitted in relaxed diet
			lactose	galactose from fruit and vegetables	galactose from galactosides	galactose restricted from offal		Patient request	Dietitian does not consider strict diet necessary	Patient remains well and poor adherence	Metabolic control satisfactory using G-I-P	
UK	11	109	11/11	0/11	0/11	0/11	4/11	4/11	1/1	4/11	0	Lactose containing ingredients in manufactured foods
Germany	6	65	6/6	0/6	0/6	4/6	2/6	1/6	1/6	1/6	1/6 centres in patients >14y age	Lactose containing ingredients in manufactured foods
Netherlands	5	51	5/5	0/5	0/5	0/5	3/5	2/5	3/5	1/5	0	Lactose containing ingredients in manufactured foods
Belgium	4	21	4/4	1/4	1/4	1/4	3/4	0	2/4	2/4	0	3/4 centres lactose containing ingredients in manufactured foods
Australia	2	54	2/2	0/2	1/2	1/2	0/2	1/2	0	0	0	None
France	2	21	2/2	0/2	0/2	0/2	2/2	0	1/2	2/2	2/2 in centres in patients >10y age	Diet relaxed to a lactose-free diet only
Italy	2	19	2/2	2/2	2/2	2/2	0/2	0	0	0	0	None
Spain	2	16	2/2	1/2	2/2	2/2	0/2	0	0	0	0	None
Sweden	2	11	2/2	0/2	0/2	1/2	0/2	0	0	0	0	None
New Zealand	1	44	1/1	0/1	0/1	0/1	1/1	1/1	1/1	1/1	0	Lactose containing ingredients in manufactured foods
Norway	1	4	1/1	0/1	0/1	0/1	0/1	0	0	0	0	None
Switzerland	1	3	1/1	0/1	0/1	1/1	0/1	0	0	0	0	None
TOTAL	39	418	39/39	4/39	6/39	12/39	15/39	9/39	9/39 (23%)	11/39	3/39	

			(100%)	(10%)	(15%)	(31%)	(38%)	(23%)		(28%)	(8%)	
--	--	--	--------	-------	-------	-------	-------	-------	--	-------	------	--

Definitions: *lactose restriction*: avoidances of animal milk and products contains animal milk e.g. yoghurt, ice cream, lactose in manufactured foods; *galactose-restriction from fruit and vegetables*: avoidance of high galactose containing fruit/vegetables e.g. tomatoes, kiwi fruits, banana; *avoidance of galactosides* e.g. peas, beans, lentils, cocoa; *restriction of galactose storage organs* e.g. offal: liver, kidney, and eggs.

Highlights

- All centres treating adults with galactosaemia restrict lactose.
- Some centres still restrict galactose in fruit, vegetables, lentils & offal in adults
- Patient led modest lactose relaxation (trace amounts) occurs in some centres
- 32% of adult patients were lost to dietetic follow-up.